Publication:
Pediatric-onset chronic inflammatory demyelinating polyneuropathy: A multicenter study

No Thumbnail Available

Date

2023-05-26

Authors

Ayanoğlu, Müge
Bodur, Muhittin

Authors

Uzan, Gamze Sarıkaya
Vural, Atay
Yüksel, Deniz
Aksoy, Erhan
Öztoprak, Ülkühan
Canpolat, Mehmet
Öztürk, Selcan
Yıldırım, Çelebi
Güleç, Ayten
Per, Hüseyin

Journal Title

Journal ISSN

Volume Title

Publisher

Elsevier Science Inc

Research Projects

Organizational Units

Journal Issue

Abstract

Background: To evaluate the clinical features, demographic features, and treatment modalities of pediatric-onset chronic inflammatory demyelinating polyneuropathy (CIDP) in Turkey. Methods: The clinical data of patients between January 2010 and December 2021 were reviewed retrospectively. The patients were evaluated according to the Joint Task Force of the European Federation of Neurological Societies and the Peripheral Nerve Society Guideline on the management of CIDP (2021). In addition, patients with typical CIDP were divided into two groups according to the first-line treatment modalities (group 1: IVIg only, group 2: IVIg + steroid). The patients were further divided into two separate groups based on their magnetic resonance imaging (MRI) characteristics. Results: A total of 43 patients, 22 (51.2%) males and 21 (48.8%) females, were included in the study. There was a significant difference between pretreatment and post-treatment modified Rankin scale (mRS) scores (P < 0.05) of all patients. First-line treatments include intravenous immunoglobulin (IVIg) (n = 19, 4 4.2%), IVIg + steroids (n = 20, 46.5%), steroids (n = 1, 2.3%), IVIg + steroids + plasmapheresis (n = 1, 2.3%), and IVIg + plasmapheresis (n = 1, 2.3%). Alternative agent therapy consisted of azathioprine (n = 5), rituximab (n = 1), and azathioprine + mycophenolate mofetil + methotrexate (n = 1). There was no difference between the pretreatment and post-treatment mRS scores of groups 1 and 2 (P > 0.05); however, a significant decrease was found in the mRS scores of both groups with treatment (P < 0.05). The patients with abnormal MRI had significantly higher pretreatment mRS scores compared with the group with normal MRI (P < 0.05). Conclusions: This multicenter study demonstrated that first-line immunotherapy modalities (IVIg vs IVIg + steroids) had equal efficacy for the treatment of patients with CIDP. We also determined that MRI features might be associated with profound clinical features, but did not affect treatment response.

Description

Keywords

Polyradiculoneuropathy, Features, Immunotherapy, Diagnosis, Children, Nerves, Cidp, Mri, Chronic inflammatory demyelinating, Polyneuropathy, Childhood, Immunotherapy, Ivig, Steroids, Neurofascin antibodies, Science & technology, Life sciences & biomedicine, Clinical neurology, Pediatrics, Neurosciences & neurology

Citation

4

Views

0

Downloads

Search on Google Scholar